Exicure

E645747

Exicure is a biotechnology company focused on developing nucleic acid therapeutics using its proprietary spherical nucleic acid (SNA) technology platform.

Try in SPARQL Jump to: Statements Referenced by

Statements (40)

Predicate Object
instanceOf biotechnology company
public company
aimsTo expand therapeutic applications of nucleic acids
improve delivery of nucleic acid drugs
basedOnResearchOf Chad Mirkin NERFINISHED
develops therapeutics for genetic disorders
therapeutics for immuno-oncology
therapeutics for neurology
focusesOn nucleic acid therapeutics
foundedBy Chad Mirkin NERFINISHED
foundedIn 2011
hasBusinessModel drug discovery and development
strategic collaborations with larger pharmaceutical companies
hasCollaboration Allergan (now part of AbbVie) NERFINISHED
Ipsen NERFINISHED
hasIntellectualProperty patents on SNA-based therapeutics
patents on spherical nucleic acid constructs
hasPipeline clinical-stage SNA-based therapeutics
preclinical SNA-based therapeutics
hasTechnologyPlatform spherical nucleic acid (SNA) platform
headquarteredIn United States NERFINISHED
industry biotechnology
listedOn NASDAQ
originatesFrom Northwestern University nanotechnology research
researchArea dermatology applications of nucleic acids
neurological disease applications of nucleic acids
oncology applications of nucleic acids
specializesIn spherical nucleic acid drug design
technologyFeature dense nucleic acid shell on nanoparticle core
enhanced cellular uptake
improved stability of nucleic acids
potential for targeted delivery
tickerSymbol XCUR NERFINISHED
usesAbbreviation SNA NERFINISHED
usesApproach nanoparticle-based nucleic acid delivery
topical and local administration of nucleic acids
usesModality antisense oligonucleotides
oligonucleotide therapeutics
siRNA therapeutics
usesTechnology spherical nucleic acid technology

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Exicure, Inc. abbreviation Exicure